|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 7S. Outcome and EBOV Genome Equivalents in Plasma and CSF from Experiment 2** | | | | | | | |
| Treatment | Animal ID | *In vivo* outcome (day) | Plasma EBOV (GE/mL) by study day | | | | CSF at day 35 (GE/mL) |
| 4/6 | 7/9 | 8 | 28 |
| EI: Irrelevant Tc hIgG control | 1 | D8 | 1.9E6 | 2.0E10 | 2.0E10 | NT | NT |
| 2 | D7 | 1.4E7 | 5.7E10 | NT | NT | NT |
| EI: SAB-139/ V6-V8 | 3 | S | <LOQ | 4.3E5 | NT | <LOQ | <LOQ |
| 4 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 5 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 6 | S | <LOQ | 2.7E5 | NT | 1.8E5 | <LOQ |
| 7 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 8 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| DI: SAB-139/ V6-V8 | 9 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 10 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 11 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 12 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 13 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |
| 14 | S | <LOQ | <LOQ | NT | <LOQ | <LOQ |

Virus in the plasma and CSF of EBOV Makona-C05-infected NHPs was assessed by quantitative RT-PCR). Both irrelevant Tc hIgG control animals developed high viremia and died by day 8 postexposure. All EI-group animals survived, but two animals had sporadic EBOV RNA (peak 4.3E5 GE/mL). All DI-group animals survived with an undetectable amount of EBOV RNA by qPCR. Abbreviations: D: died (day); DI, delayed intervention (treatment initiated on day 3 postexposure); EBOV, Ebola virus; EI, early intervention (treatment initiated on day 1 postexposure); GE, genome equivalents; ID, identification number; S, survived; LOQ, limit of quantification; NT, not tested; Tc hIgG, transchromosomic human Immunoglobulin G.